Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001ORKA-001 maintained a favorable safety and tolerability profile through Week 2852-week EVERLAST-A dat…